Prophylaxis of acute GVHD after bone marrow transplantation from unrelated donors with C3 monitoring of cyclosporine: a multicenter prospective study.
Not Applicable
Recruiting
- Conditions
- Hematological malignancy
- Registration Number
- JPRN-UMIN000002817
- Lead Sponsor
- Cellular Transplantation Biology, Kanazawa University Graduate School of Medical Science
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
Not provided
Exclusion Criteria
1) Non-myeloablative allogeneic transplantation 2) Past transplantation history 3) T-cell depleted transplantation 4) Use of ATG or ALG as preparative regimens 5) Serum creatinine level >= 2.0 mg/dL or >= 1.5 times the upper limit of the normal range, Ccr < 50 mL/min 6) Serum total bilirubin level >= 2.0 mg/dL, serum AST/ALT level >= 2 times the upper limit of the normal range 7) Uncontrolled hypertension 8) Uncontrolled diabetes mellitus on insulin therapy 9) Uncontrolled active infections 10) History of epilepsy 11) Other severe complications 12) Pregnant female 13) Allergic to cyclosporine 14) Any patients who are judged unsuitable for the enrollment by the attending physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of grade II-IV and grade III-IV acute GVHD within 100 days after bone marrow transplantation.
- Secondary Outcome Measures
Name Time Method